Deletion of the FHL2 gene attenuating neovascularization after corneal injury.

PURPOSE The four-and-one-half LIM domain-containing protein2 (FHL2) is a member of the four-and-a-half LIM domain-only (FHL) gene family. Although FHL2 is expressed in the cornea, its role in angiogenesis is unclear. The aim of this study was to investigate the role of the FHL2 gene in corneal angiogenesis after chemical injury. METHODS FHL2-LacZ knock-in mice were used to trace FHL2 gene expression before and after corneal injury. Corneal angiogenesis between FHL2-null mice and wild-type mice that underwent chemical and mechanical denudation of corneal and limbal epithelium were compared. New growth vessel density was assessed by CD31 staining and was analyzed using image analysis software. Levels of vascular endothelial growth factor (VEGF) and cyclooxygenase (COX)-2 proteins were determined by Western blot assay. RESULTS beta-Galactosidase staining of corneal tissue in FHL2-LacZ knock-in mice revealed that FHL2 gene expression is upregulated in the corneal epithelium after corneal injury. Ten days after injury, corneal neovascularization was observed in control and FHL2-null mice. New corneal vessel density was found to be lower in the FHL2-null mice injury group than in the wild-type mice injury group. Western blot analysis showed that VEGF and COX-2 protein levels were higher after chemical injury in FHL2-null mice and wild-type mice. However, the upregulated VEGF protein was significantly lower in the FHL2-null mice than in the wild-type mice. CONCLUSIONS The decreased chemical-induced corneal angiogenesis found in the FHL2-null mice in this study indicated that FHL2 protein plays a role in inhibiting inflammatory angiogenesis.

[1]  Jian-xing Ma,et al.  Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy , 2007, Progress in Retinal and Eye Research.

[2]  Ear Infirmary CORNEAL ANGIOGENIC PRIVILEGE: ANGIOGENIC AND ANTIANGIOGENIC FACTORS IN CORNEAL AVASCULARITY, VASCULOGENESIS, AND WOUND HEALING (AN AMERICAN OPHTHALMOLOGICAL , 2006 .

[3]  U. Moens,et al.  The multifunctional roles of the four-and-a-half-LIM only protein FHL2 , 2006, Cellular and Molecular Life Sciences CMLS.

[4]  T. Tsukada,et al.  FHL5, a novel actin-binding protein, is highly expressed in eel gill pillar cells and responds to wall tension. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[5]  M. Beckerle,et al.  The LIM domain: from the cytoskeleton to the nucleus , 2004, Nature Reviews Molecular Cell Biology.

[6]  R. Schüle,et al.  The LIM-only Proteins FHL2 and FHL3 Interact with α- and β-Subunits of the Muscle α7β1 Integrin Receptor* , 2004, Journal of Biological Chemistry.

[7]  R. Schüle,et al.  Extracellular Signal-Regulated Kinase 2 Interacts with and Is Negatively Regulated by the LIM-Only Protein FHL2 in Cardiomyocytes , 2004, Molecular and Cellular Biology.

[8]  R. Schüle,et al.  The LIM-only proteins FHL2 and FHL3 interact with alpha- and beta-subunits of the muscle alpha7beta1 integrin receptor. , 2004, The Journal of biological chemistry.

[9]  Jonathan T. Lu,et al.  Gene-engineered models for genetic manipulation and functional analysis of the cardiovascular system in mice. , 2003, Chang Gung medical journal.

[10]  Sung-Chul Lim,et al.  Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma. , 2003, Oncology reports.

[11]  J. Ambati,et al.  Inhibition of Corneal Neovascularization by Genetic Ablation of CCR2 , 2003, Cornea.

[12]  R. Gilbert,et al.  COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. , 2003, Investigative ophthalmology & visual science.

[13]  M. Buendia,et al.  Identification of the LIM Protein FHL2 as a Coactivator of β-Catenin* , 2003, The Journal of Biological Chemistry.

[14]  J. Ambati,et al.  Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. , 2003, Investigative ophthalmology & visual science.

[15]  M. Buendia,et al.  Identification of the LIM protein FHL2 as a coactivator of beta-catenin. , 2003, The Journal of biological chemistry.

[16]  M. Kühl,et al.  The LIM-only protein FHL2 interacts with β-catenin and promotes differentiation of mouse myoblasts , 2002, The Journal of cell biology.

[17]  J. Ambati,et al.  Angiostatin inhibits and regresses corneal neovascularization. , 2002, Archives of ophthalmology.

[18]  S. Fan,et al.  Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. , 2001, American journal of clinical pathology.

[19]  Y. Sugisaki,et al.  Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. , 2001, The American journal of pathology.

[20]  P. Sassone-Corsi,et al.  Transcriptional cascades during spermatogenesis: pivotal role of CREM and ACT , 2001, Molecular and Cellular Endocrinology.

[21]  R. Bassel-Duby,et al.  Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to &bgr;-Adrenergic Stimulation , 2001, Circulation.

[22]  M. Sunday,et al.  Differential expression of VEGF isoforms in mouse during development and in the adult , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.

[23]  D. Azar,et al.  Corneal neovascularization. , 2001, Current opinion in ophthalmology.

[24]  L. Liotta,et al.  Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  A. Ghosh,et al.  Cyclooxygenase-2-mediated angiogenesis in carrageenin-induced granulation tissue in rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[26]  J. Ross,et al.  FHL2 (SLIM3) Is Not Essential for Cardiac Development and Function , 2000, Molecular and Cellular Biology.

[27]  L. Aiello,et al.  Role of vascular endothelial growth factor in diabetic vascular complications. , 2000, Kidney international. Supplement.

[28]  C. Humpel,et al.  Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. , 2000, Investigative ophthalmology & visual science.

[29]  Qiang Zhou,et al.  Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system , 2000, Mechanisms of Development.

[30]  S. Yamashina,et al.  Cyclo‐oxygenase‐2 enhances basic fibroblast growth factor‐induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants , 2000, British journal of pharmacology.

[31]  S. Dey,et al.  Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.

[32]  K. Seibert,et al.  Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.

[33]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[34]  R. Harvey,et al.  An HF-1a/HF-1b/MEF-2 combinatorial element confers cardiac ventricular specificity and established an anterior-posterior gradient of expression. , 1996, Development.

[35]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[36]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.